BioVie Inc. reported a net loss of approximately $5.1 million for the three months ended September 30, 2025, compared to a net loss of $4.2 million for the same period in 2024. The increase in net loss was primarily driven by a rise in research and development expenses, which totaled approximately $2.9 million, up from $2.0 million in the prior year. This increase reflects the costs associated with the development of new clinical studies, including the Sunrise PD Phase 2 study and the Long COVID program. Total operating expenses for the quarter were approximately $5.3 million, compared to $4.1 million in the previous year, marking a significant increase attributed to both R&D and general administrative expenses.
In terms of financial position, BioVie reported total assets of approximately $26.8 million as of September 30, 2025, an increase from $21.6 million at the end of the previous fiscal quarter. The company’s cash and cash equivalents rose to approximately $25.0 million, up from $17.5 million at the end of June 2025. This increase was bolstered by net proceeds of approximately $10.5 million from a public offering completed in August 2025, which involved the issuance of 5,620,000 units of common stock and warrants. The company’s stockholders’ equity also improved, reaching approximately $24.9 million, compared to $19.0 million in the prior quarter.
Operationally, BioVie is focused on advancing its clinical programs, particularly its investigational drug bezisterim (NE3107), which is being evaluated for the treatment of neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease, as well as long COVID. The company has initiated a new Phase 2b study for bezisterim in patients with new-onset Parkinson’s disease, which commenced in April 2025. Additionally, the company received a $13.1 million grant from the U.S. Department of Defense to support its long COVID program, which is expected to enhance its research capabilities.
Despite these developments, BioVie remains in a pre-revenue stage and does not anticipate generating revenue in the near future. The company reported an accumulated deficit of approximately $357.3 million as of September 30, 2025. Management has indicated that future operations will depend heavily on the success of ongoing clinical trials and the ability to secure additional financing. The company is actively pursuing various funding strategies, including equity sales and potential loans, to support its operations and clinical development efforts. However, there is substantial doubt regarding the company’s ability to continue as a going concern without securing sufficient financing.
About BIOVIE INC.
BioVie Inc. is a clinical-stage biopharmaceutical company developing innovative drug therapies targeting neurological and neurodegenerative disorders, including Alzheimer’s and Parkinson’s diseases, long COVID, and advanced liver cirrhosis. Its key products include bezisterim, an oral anti-inflammatory agent addressing neuroinflammation and insulin resistance, and BIV201, a novel terlipressin formulation for liver disease complications. BioVie focuses on advancing clinical trials and leveraging proprietary formulations and intellectual property to address significant unmet medical needs.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.